האגודה למלחמה בסרטן - במה - גיליון מס' 24 - אוגוסט 2021

The Journey Of CAR-T Starts Here

Kymriah is indicated for the treatment of: ● Paediatric and young adult patients up to 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. ● Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ● Limitation of Use: Kymriah is not indicated for treatment of patients with primary or secondary central nervous system lymphoma.

Dear Physician, for further information please refer to the prescribing information as approved by the Israeli Ministry of Health.

KYH 2-21 MAY 21

Novartis Israel Ltd | 6 Tozeret Haaretz street, Tel Aviv P.O.B 7126 | Tel: 972-3-9201111 Fax: 972-3-9229331